Q-omics provides the consensus-scored C1orf43 profile across patient tissues and cancer cell-line models. C1orf43 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C1orf43 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, C1orf43 RNA expression shows 18,679 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where C1orf43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf43 survival associations across molecular data types. C1orf43 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf43 RNA expression–survival associations across cancer types. High C1orf43 expression shows unfavorable associations in UVM, ACC, CESC, KIRP and LIHC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for C1orf43 RNA expression.
This table summarizes C1orf43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C1orf43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf43 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, KIRC, LIHC and STAD. The BLCA box plot shows higher C1orf43 RNA expression in tumor versus normal tissue (log2 FC = +0.714, t-test p < 0.001).
This table shows molecular features associated with C1orf43 in patient tissues and cancer cell lines. In patient samples, C1orf43 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
